Aligos Therapeutics, Inc.
ALGS
$7.34
$0.395.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 81.56% | -12.36% | 2.05% | 46.52% | -49.65% |
| Total Depreciation and Amortization | -9.44% | -41.45% | -52.76% | -62.54% | -66.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -201.94% | 271.65% | 232.87% | -180.11% | 259.33% |
| Change in Net Operating Assets | 23.57% | 63.71% | 17.78% | 70.95% | 47.98% |
| Cash from Operations | -2.18% | 6.87% | 12.10% | 0.57% | -2.21% |
| Capital Expenditure | -236.15% | -242.20% | -116.84% | -28.40% | -584.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -106.01% | 59.47% | -8.96% | 141.53% | -140.33% |
| Cash from Investing | -106.94% | 58.62% | -9.15% | 141.31% | -140.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 83.13% | -22.73% | 18.33% | 29.67% | 13.54% |
| Issuance of Common Stock | 23,157.53% | 471.38% | 471.41% | 467.86% | -97.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 28,529.58% | 15.21% | 15.29% | 15.63% | -99.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.05% | 118.87% | 42.31% | 190.50% | -281.67% |